The main objective of this non-interventional (retrospective) study is to describe the general treatment patterns, effectiveness, and safety of ceftazidime-avibactam in real-world settings in India. Eligible patients would be adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice from 01 June 2019 to 01 April 2020. Data of 500 patients will be collected through the abstraction of hospital medical records (electronic) if available or through the individual patient medical record in case electronic records are not available.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Clinical Symptom Improvement at Day 3
Timeframe: Day 3 after ceftazidime-avibactam initiation
Number of Participants With Treatment Success at Day 7
Timeframe: Day 7 after ceftazidime-avibactam initiation
Number of Participants With Treatment Success at Day 14 or End of Treatment
Timeframe: Day 14 or End of Treatment after ceftazidime-avibactam initiation, whichever was earlier
Number of Participants With Microbiological Success at Day 7
Timeframe: Day 7 after ceftazidime-avibactam initiation
Number of Participants With Microbiological Success at Day 14 or End of Treatment
Timeframe: Day 14 or End of Treatment after ceftazidime-avibactam initiation, whichever was earlier
Number of Participants With Serious Adverse Events and Non-Serious Adverse Events With Explicit Attribution to Ceftazidime-Avibactam
Timeframe: Up to 30 days post treatment completion with ceftazidime-avibactam, death or discharge; whichever was first (Up to maximum of 49 days)